Review Of BMS's CAR-T Therapy Liso-Cel Gets Under Way At EMA
There Are Six Additions To The List Of Products Seeking EU Approval
Executive Summary
Bristol Myers Squibb's lisocabtagene maraleucel, UCB's bimekizumab and Rhythm Pharmaceuticals' setmelanotide are among the six latest additions to the list of products under review at the European Medicines Agency.